Literature DB >> 17516312

[Quality indicators for diagnostic and therapy of rectal carcinoma].

R Bittner1, J Burghardt, E Gross, R T Grundmann, P Hermanek, C Isbert, T Junginger, F Köckerling, S Merkel, G Möslein, H-R Raab, J Roder, G Ruf, W Schwenk, J Strassburg, A Tannapfel, A de Vries, H Zühlke.   

Abstract

Diagnostic and treatment of rectal cancer need a continuous quality assessment. Indicators of quality were compiled as indicator profile for a summarizing evaluation. The indicators selected should potentially show an appreciable variation of the quality target and in addition should be decisive for the outcome. For the evaluation of the clinical diagnostic the frequency of the determination of the pretherapeutic T, N and M categories and the proportion of pT 1-tumors were chosen, for the pathological diagnostic the number of histologically examined lymph nodes and the proportion of lymphnode positive patients. Process quality of treatment was defined by the following indicators: proportion of tumor excision, of definite therapy by local tumor removal, of neo-adjuvant long-term radiochemotherapy, of adjuvant treatment in patients not selected for neoadjuvant therapy, of total / partial mesorectal excision, of abdomino-perineal resection, postoperative mortality, frequency of clinically apparent anastomotic leakage, and of neurogenic bladder dysfunction at hospital discharge. The indicators for the quality of the performance of treatment were differentiated between surrogate indicators that can be determined immediately after accomplishment of primary surgical therapy giving strong clues for the further course of disease at an early date, and definite indicators. Important surrogate indicators comprise the occurrence of intraoperative local tumor cell dissemination, R 1 / 2-resection, pathohistologically CRM-positive tumor resection, and the quality of mesorectal excision (proportion of incomplete mesorectal excision). The definite indicators include the 5-year local recurrence rate and the 5-year overall survival rate. The corresponding quantifying parameters for the individual indicators are specified in this paper with precise figures.

Entities:  

Mesh:

Year:  2007        PMID: 17516312     DOI: 10.1055/s-2007-960623

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  11 in total

1.  Quality management in rectal carcinoma: what is feasible?

Authors:  Susanne Merkel; Daniela Klossek; Jonas Göhl; Thomas Papadopoulos; Werner Hohenberger; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2009-06-02       Impact factor: 2.571

2.  [Tumors of the lower gastrointestinal tract : Indication and extent of lymph node dissection].

Authors:  S Merkel; K Weber; A Perrakis; J Göhl; W Hohenberger
Journal:  Chirurg       Date:  2010-02       Impact factor: 0.955

3.  Association of certification, improved quality and better oncological outcomes for rectal cancer in a specialized colorectal unit.

Authors:  Annika Jacob; Wolfgang Albert; Thomas Jackisch; Christiane Jakob; Anja Sims; Helmut Witzigmann; Sören Torge Mees; Sigmar Stelzner
Journal:  Int J Colorectal Dis       Date:  2020-11-09       Impact factor: 2.571

4.  Evaluation of quality indicators following implementation of total mesorectal excision in primarily resected rectal cancer changed future management.

Authors:  Paul M Schneider; Daniel Vallbohmer; Yvonne Ploenes; Georg Lurje; Ralf Metzger; Frederike C Ling; Jan Brabender; Uta Drebber; Arnulf H Hoelscher
Journal:  Int J Colorectal Dis       Date:  2011-02-22       Impact factor: 2.571

5.  Practicability of quality goals for the treatment of rectal cancer.

Authors:  Sigmar Stelzner; Gunter Hellmich; Gunter Haroske; Erik Puffer; Thomas Jackisch; Helmut Witzigmann
Journal:  Int J Colorectal Dis       Date:  2010-06-12       Impact factor: 2.571

Review 6.  [Intra-operative local tumor cell dissemination in rectal carcinoma surgery: effect of operation principles and neoadjuvant therapy].

Authors:  S Merkel; W Hohenberger; P Hermanek
Journal:  Chirurg       Date:  2010-08       Impact factor: 0.955

7.  [Problems in the treatment of upper rectal carcinoma].

Authors:  T Junginger; P Hermanek
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

8.  [Lymph node dissection after primary surgery and neoadjuvant radiochemotherapy of rectal cancer. Interim analysis of a multicenter prospective observational study (OCUM)].

Authors:  M E Kreis; C A Maurer; R Ruppert; H Ptok; J Strassburg; T Junginger; S Merkel; P Hermanek
Journal:  Chirurg       Date:  2015-12       Impact factor: 0.955

9.  Magnetic resonance imaging (MRI)-based indication for neoadjuvant treatment of rectal carcinoma and the surrogate endpoint CRM status.

Authors:  Joachim Strassburg; Theo Junginger; Trong Trinh; Olaf Püttcher; Katja Oberholzer; Richard J Heald; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2008-07-17       Impact factor: 2.571

10.  [Spincter preservation after selective chemoradiotherapy of rectal cancer. Interim results of the OCUM study].

Authors:  J Baral; M R Schön; R Ruppert; H Ptok; J Strassburg; P Brosi; M E Kreis; A Lewin; J Sauer; S Sawicki; L Schiffmann; G Winde; T Junginger; S Merkel; P Hermanek
Journal:  Chirurg       Date:  2015-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.